Hualan Biological Vaccine Balance Sheet Health
Financial Health criteria checks 5/6
Hualan Biological Vaccine has a total shareholder equity of CN¥5.9B and total debt of CN¥300.0M, which brings its debt-to-equity ratio to 5.1%. Its total assets and total liabilities are CN¥7.3B and CN¥1.3B respectively. Hualan Biological Vaccine's EBIT is CN¥774.4M making its interest coverage ratio -9.7. It has cash and short-term investments of CN¥2.8B.
Key information
5.1%
Debt to equity ratio
CN¥300.00m
Debt
| Interest coverage ratio | -9.7x |
| Cash | CN¥2.83b |
| Equity | CN¥5.92b |
| Total liabilities | CN¥1.34b |
| Total assets | CN¥7.26b |
Recent financial health updates
No updates
Recent updates
Potential Upside For Hualan Biological Vaccine Inc. (SZSE:301207) Not Without Risk
Jul 25
Hualan Biological Vaccine's (SZSE:301207) Upcoming Dividend Will Be Larger Than Last Year's
Jun 11Revenue Downgrade: Here's What Analysts Forecast For Hualan Biological Vaccine Inc. (SZSE:301207)
Apr 03Hualan Biological Vaccine Inc. Just Missed Revenue By 9.2%: Here's What Analysts Think Will Happen Next
Apr 02Hualan Biological Vaccine Inc.'s (SZSE:301207) Subdued P/E Might Signal An Opportunity
Apr 01An Intrinsic Calculation For Hualan Biological Vaccine Inc. (SZSE:301207) Suggests It's 31% Undervalued
Mar 04Financial Position Analysis
Short Term Liabilities: 301207's short term assets (CN¥4.4B) exceed its short term liabilities (CN¥1.3B).
Long Term Liabilities: 301207's short term assets (CN¥4.4B) exceed its long term liabilities (CN¥42.9M).
Debt to Equity History and Analysis
Debt Level: 301207 has more cash than its total debt.
Reducing Debt: 301207's debt to equity ratio has increased from 0% to 5.1% over the past 5 years.
Debt Coverage: 301207's debt is well covered by operating cash flow (249.7%).
Interest Coverage: 301207 earns more interest than it pays, so coverage of interest payments is not a concern.